Validation of telomerase and survivin as anticancer therapeutic targets using ribozymes and small-interfering RNAs

Nadia Zaffaroni, Marzia Pennati, Marco Folini

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In recent years expanding knowledge about basic biology and a detailed understanding of the molecular pathways involved in tumor cell growth and progression have allowed the identification of numerous genes as potential therapeutic targets. Studies in which the expression of these genes was manipulated by antisense strategies have provided clues as to how we can intervene to specifically kill tumor cells or sensitize them to conventional chemical and physical antitumor therapies. Such tumor specificity can only be obtained by exploiting a basic difference between normal and malignant cells. In this context, targeting cytoprotective factors such as telomerase and survivin is particularly attractive because of their almost selective expression in tumor cells and their proven association with disease progression. This chapter summarizes the results obtained with ribozymes and small-interfering RNAs in the functional validation of these two targets in cell cultures and animal tumor models.

Original languageEnglish
Title of host publicationMethods in Molecular Biology
Pages239-263
Number of pages25
Volume361
DOIs
Publication statusPublished - Feb 5 2007

Publication series

NameMethods in Molecular Biology
Volume361
ISSN (Print)10643745

Keywords

  • Human cancer
  • Ribozyme
  • siRNA
  • Survivin
  • Telomerase

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Fingerprint

Dive into the research topics of 'Validation of telomerase and survivin as anticancer therapeutic targets using ribozymes and small-interfering RNAs'. Together they form a unique fingerprint.

Cite this